April 6, 2015
Astellas Pharma said on April 3 that its oral androgen receptor inhibitor Xtandi (enzalutamide) significantly extended progression-free survival (PFS) in men with non-metastatic or metastatic castration-resistant prostate cancer, compared to the anti-androgen agent bicalutamide. In the STRIVE PII clinical trial...read more